These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29599087)

  • 1. A novel method for strict intranasal delivery of non-replicating RSV vaccines in cotton rats and non-human primates.
    Citron MP; Patel M; Purcell M; Lin SA; Rubins DJ; McQuade P; Callahan C; Gleason A; Petrescu I; Knapp W; Orekie C; Chamarthy S; Wen Z; Touch S; Pine M; Fontenot J; Douglas C; Liang X; Espeseth AS
    Vaccine; 2018 May; 36(20):2876-2885. PubMed ID: 29599087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
    Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats.
    O'Konek JJ; Makidon PE; Landers JJ; Cao Z; Malinczak CA; Pannu J; Sun J; Bitko V; Ciotti S; Hamouda T; Wojcinski ZW; Lukacs NW; Fattom A; Baker JR
    Hum Vaccin Immunother; 2015; 11(12):2904-12. PubMed ID: 26307915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age.
    Guichelaar T; Hoeboer J; Widjojoatmodjo MN; Reemers SS; van Els CA; Otten R; van Remmerden Y; Boes J; Luytjes W
    J Virol; 2014 Sep; 88(17):9744-50. PubMed ID: 24920795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
    Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Live Attenuated Respiratory Syncytial Virus Vaccine Candidate with Mutations in the L Protein SAM Binding Site and the G Protein Cleavage Site Is Protective in Cotton Rats and a Rhesus Macaque.
    Jenkins T; Wang R; Harder O; Xue M; Chen P; Corry J; Walker C; Teng M; Mejias A; Ramilo O; Niewiesk S; Li J; Peeples ME
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infection-enhancing lipopeptides do not improve intranasal immunization of cotton rats with a delta-G candidate live-attenuated human respiratory syncytial virus vaccine.
    Tien Nguyen D; Boes J; van Amerongen G; van Remmerden Y; Yüksel S; Guichelaar T; Osterhaus AD; de Swart RL
    Hum Vaccin Immunother; 2013 Dec; 9(12):2578-83. PubMed ID: 23955280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cotton rat Sigmodon hispidus model of respiratory syncytial virus infection.
    Boukhvalova MS; Blanco JC
    Curr Top Microbiol Immunol; 2013; 372():347-58. PubMed ID: 24362698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
    Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
    Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates.
    Grunwald T; Tenbusch M; Schulte R; Raue K; Wolf H; Hannaman D; de Swart RL; Uberla K; Stahl-Hennig C
    J Virol; 2014 Apr; 88(8):3997-4007. PubMed ID: 24453366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
    Hwang HS; Lee YT; Kim KH; Park S; Kwon YM; Lee Y; Ko EJ; Jung YJ; Lee JS; Kim YJ; Lee YN; Kim MC; Cho M; Kang SM
    Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation of the respiratory syncytial virus fusion protein with a polymer-based combination adjuvant promotes transient and local innate immune responses and leads to improved adaptive immunity.
    Sarkar I; Garg R; van Drunen Littel-van den Hurk S
    Vaccine; 2016 Sep; 34(42):5114-5124. PubMed ID: 27591951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical assessment of safety of maternal vaccination against respiratory syncytial virus (RSV) in cotton rats.
    Blanco JCG; Pletneva LM; Otoa RO; Patel MC; Vogel SN; Boukhvalova MS
    Vaccine; 2017 Jul; 35(32):3951-3958. PubMed ID: 28624306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of genetic background and delivery route on the preclinical properties of a live attenuated RSV vaccine.
    Groppo R; DiNapoli J; Il Jeong K; Kishko M; Jackson N; Kleanthous H; Delagrave S; Zhang L; Parrington M
    PLoS One; 2018; 13(6):e0199452. PubMed ID: 29920563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 of Sigmodon hispidus: Gene identification, characterization and preliminary evaluation of expression in inactivated RSV vaccine-induced enhanced respiratory disease.
    Muralidharan A; Larocque L; Russell M; Creskey M; Li C; Chen W; Van Domselaar G; Cao J; Cyr T; Rosu-Myles M; Wang L; Li X
    Sci Rep; 2019 Aug; 9(1):11638. PubMed ID: 31406266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
    Shafique M; Wilschut J; de Haan A
    Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.
    Tang RS; Spaete RR; Thompson MW; MacPhail M; Guzzetta JM; Ryan PC; Reisinger K; Chandler P; Hilty M; Walker RE; Gomez MM; Losonsky GA
    Vaccine; 2008 Nov; 26(50):6373-82. PubMed ID: 18822334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naïve infants.
    Browne SK; Beeler JA; Roberts JN
    Vaccine; 2020 Jan; 38(2):101-106. PubMed ID: 31706809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.